Cefepime Market Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The global cefepime market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Cefepime is a cephalosporin antibiotic used to treat certain infections caused by bacteria including pneumonia, urinary tract infection, and kidney infections. The rise in the prevalence of urinary tract infections (UTI) is anticipated to drive the growth of the global cefepime market. For instance, according to the data published by National Center for Biotechnology Center (NCBI) in 2019, UTIs are the most common outpatient infections, with a lifetime incidence of 50.0-60.0% in women. The prevalence of UTI increases with the age, and in women aged 65 is approximately double the rate seen in the female population overall. The prevalence in women over 65 years of age is approximately 20.0%, compared with approximately 11.0% of the population. Moreover, 50.0% and 60.0% of adult women are projected to have UTIs at least once in their lifetime, and close to 10.0% of postmenopausal women indicate that they had a UTI in the previous year.

Moreover, the rise in the prevalence of pneumonia is anticipated to drive the growth of the global imipenem API market. For instance, according to the data published by World Health Organization (WHO) in 2021, pneumonia registered for 14.0% of all mortalities in children under 5 years old, and 740180 mortalities occurred in children in 2019. The WHO states that pneumonia can be protected with simple interventions, and can be treated with low cost, low tech medication, and care. Also, according to the data published by NCBI, pneumonia is the eighth leading cause of mortality and first among infectious causes of mortality. Further, pneumonia varies between 1.5 to 14 cases per 1000 people and is affected by geography, season, and population characteristics. Thus, the rise in the prevalence of pneumonia is anticipated to drive the demand for the global cefepime market.

Looking towards the demand for cefepime, key market players are adopting various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in March 2022, Venatrox Pharmacueticals Inc., in collaboration with GARDP had announced the positive results from its pivotal phase 3 evaluating cefepime-taniborbactum as a treatment option for hospitalized adult patients with urinary tract infection. Moreover, since April 2020, GARDP and Venatrox pharmaceutical Inc had been working to accelerate the development of cefepime and a new drug application is anticipated to be filled with USFDA in the fourth quarter of 2022. Thus, such clinical trials are anticipated to drive the growth of the global cefepime market.

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape-Pfizer Inc, Baxter International Inc, and B.Braun Melsungen AG among others.

 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Cefepime Market Report by Segment

By Type

• Intramuscular Injection
• Intravenous Drug Delivery

By Application

• Lower Respiratory Tract Infection
• Skin and Soft tissue Infection
• Urinary Tract Infection
• Abdominal Cavity Infection
• Gynecologic Infection
• Neutrophilic Fever
• Sepsis